JP2015227351A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015227351A5 JP2015227351A5 JP2015140309A JP2015140309A JP2015227351A5 JP 2015227351 A5 JP2015227351 A5 JP 2015227351A5 JP 2015140309 A JP2015140309 A JP 2015140309A JP 2015140309 A JP2015140309 A JP 2015140309A JP 2015227351 A5 JP2015227351 A5 JP 2015227351A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antimetabolite
- cancer
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55357804P | 2004-03-15 | 2004-03-15 | |
| US60/553,578 | 2004-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014091125A Division JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Ｓｎｓ−５９５、及びその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016248041A Division JP2017095471A (ja) | 2004-03-15 | 2016-12-21 | Ｓｎｓ−５９５、及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015227351A JP2015227351A (ja) | 2015-12-17 |
| JP2015227351A5 true JP2015227351A5 (enExample) | 2016-02-04 |
| JP6352863B2 JP6352863B2 (ja) | 2018-07-04 |
Family
ID=34993432
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503972A Expired - Fee Related JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2007503987A Expired - Fee Related JP5317472B2 (ja) | 2004-03-15 | 2005-03-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2011135675A Pending JP2011225590A (ja) | 2004-03-15 | 2011-06-17 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2012036919A Pending JP2012140442A (ja) | 2004-03-15 | 2012-02-23 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2014091125A Expired - Fee Related JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2014180862A Expired - Fee Related JP6261477B2 (ja) | 2004-03-15 | 2014-09-05 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2015140309A Expired - Fee Related JP6352863B2 (ja) | 2004-03-15 | 2015-07-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2016248041A Pending JP2017095471A (ja) | 2004-03-15 | 2016-12-21 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2018038834A Pending JP2018119977A (ja) | 2004-03-15 | 2018-03-05 | Ｓｎｓ−５９５、及びその使用方法 |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503972A Expired - Fee Related JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2007503987A Expired - Fee Related JP5317472B2 (ja) | 2004-03-15 | 2005-03-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2011135675A Pending JP2011225590A (ja) | 2004-03-15 | 2011-06-17 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2012036919A Pending JP2012140442A (ja) | 2004-03-15 | 2012-02-23 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2014091125A Expired - Fee Related JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2014180862A Expired - Fee Related JP6261477B2 (ja) | 2004-03-15 | 2014-09-05 | Ｓｎｓ−５９５、及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016248041A Pending JP2017095471A (ja) | 2004-03-15 | 2016-12-21 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2018038834A Pending JP2018119977A (ja) | 2004-03-15 | 2018-03-05 | Ｓｎｓ−５９５、及びその使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (12) | US7989468B2 (enExample) |
| EP (4) | EP1725233B1 (enExample) |
| JP (9) | JP5096913B2 (enExample) |
| KR (1) | KR101169825B1 (enExample) |
| CN (5) | CN104324029A (enExample) |
| AT (2) | ATE451924T1 (enExample) |
| AU (3) | AU2005222607B2 (enExample) |
| BR (1) | BRPI0508700A (enExample) |
| CA (3) | CA2559652C (enExample) |
| CY (2) | CY1109741T1 (enExample) |
| DE (2) | DE602005025738D1 (enExample) |
| DK (3) | DK1729770T3 (enExample) |
| ES (3) | ES2358267T3 (enExample) |
| HU (1) | HUE027266T2 (enExample) |
| IL (2) | IL177946A (enExample) |
| MX (2) | MX349188B (enExample) |
| NO (3) | NO338058B1 (enExample) |
| NZ (2) | NZ549557A (enExample) |
| PL (3) | PL2295056T3 (enExample) |
| PT (2) | PT1725233E (enExample) |
| SI (2) | SI1725233T1 (enExample) |
| WO (2) | WO2005089757A1 (enExample) |
| ZA (1) | ZA200607248B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE451924T1 (de) | 2004-03-15 | 2010-01-15 | Sunesis Pharmaceuticals Inc | Sns-595 und anwendungsverfahren |
| NZ553746A (en) * | 2004-09-17 | 2010-06-25 | Cylene Pharmaceuticals Inc | Quinolone analogs as cell proliferation inhibitors |
| US7652134B2 (en) * | 2004-09-17 | 2010-01-26 | Cylene Pharmaceuticals, Inc. | Methods for converting quinolone esters into quinolone amides |
| EP1926372A2 (en) * | 2005-08-19 | 2008-06-04 | Cylene Pharmaceuticals, Inc. | HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF |
| JP5374153B2 (ja) * | 2005-09-02 | 2013-12-25 | サネシス ファーマシューティカルズ， インコーポレイテッド | 癌の治療のための（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸を使用する方法 |
| US8580814B2 (en) * | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| AU2006287149B2 (en) * | 2005-09-02 | 2013-05-23 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| US8124773B2 (en) * | 2006-06-12 | 2012-02-28 | Sunesis Pharmaceuticals, Inc. | 1,8-naphthyridine compounds for the treatment of cancer |
| WO2008016678A2 (en) * | 2006-08-01 | 2008-02-07 | Sunesis Pharmaceuticals, Inc. | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| JP2009545601A (ja) | 2006-08-02 | 2009-12-24 | サネシス ファーマシューティカルズ， インコーポレイテッド | （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の組合せ使用 |
| EP2209380A4 (en) * | 2007-10-09 | 2011-09-14 | Mark T Hamann | METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF |
| AU2014277779B2 (en) * | 2007-10-22 | 2016-05-19 | Sunesis Pharmaceuticals, Inc. | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY |
| US8518872B2 (en) * | 2007-10-22 | 2013-08-27 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy |
| CA2708264C (en) * | 2007-12-10 | 2018-07-03 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| EP2382214B1 (en) | 2008-12-31 | 2017-07-19 | Sunesis Pharmaceuticals, Inc. | Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| JP5936862B2 (ja) * | 2009-02-27 | 2016-06-22 | サネシス ファーマシューティカルズ， インコーポレイテッド | Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法 |
| UA110465C2 (en) | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
| TW201120037A (en) * | 2009-10-26 | 2011-06-16 | Sunesis Pharmaceuticals Inc | Compounds and methods for treatment of cancer |
| HUE033126T2 (en) | 2012-02-27 | 2017-11-28 | Agq Tech Corporate S A | Monitoring and control of soil conditions |
| SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| RS62649B1 (sr) | 2013-03-12 | 2021-12-31 | Vertex Pharma | Inhibitori dnk-pk |
| US20160067182A1 (en) * | 2013-04-09 | 2016-03-10 | Merrimack Pharmaceuticals, Inc. | Methods and compositions for improving outcomes of liposomal chemotherapy |
| EP3016659A4 (en) * | 2013-07-02 | 2017-03-15 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-iii |
| KR102411227B1 (ko) | 2013-10-17 | 2022-06-21 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정 |
| KR101775356B1 (ko) * | 2015-07-06 | 2017-09-06 | 재단법인 아산사회복지재단 | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 |
| MX394860B (es) | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
| WO2025033367A1 (ja) * | 2023-08-04 | 2025-02-13 | 湧永製薬株式会社 | 抗腫瘍剤併用療法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US216316A (en) * | 1879-06-10 | Improvement in latches | ||
| US3021A (en) * | 1843-03-30 | Stove with elevated ovejst | ||
| US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| NZ287139A (en) * | 1994-06-14 | 1997-07-27 | Dainippon Pharmaceutical Co | Naphthyridine derivatives; preparative process and anti-tumour medicaments |
| JP4323574B2 (ja) | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | 抗腫瘍剤 |
| WO1998030902A1 (en) * | 1997-01-13 | 1998-07-16 | Kudos Pharmaceuticals Limited | Assays, agents, therapy and diagnosis relating to modulation of cellular dna repair activity |
| US20020032216A1 (en) * | 1997-03-21 | 2002-03-14 | Lg Chemical Ltd. | Salt of naphthyridine carboxylic acid derivative |
| EP1003856A1 (en) | 1997-06-05 | 2000-05-31 | Board of Regents, The University of Texas System | Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
| US6171857B1 (en) | 1997-10-17 | 2001-01-09 | Brown University Research Foundatiion | Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity |
| US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| IL124015A0 (en) * | 1998-04-08 | 1999-01-26 | Yeda Res & Dev | Pharmaceutical compositions comprising a protein |
| JP4294121B2 (ja) | 1998-06-05 | 2009-07-08 | 大日本住友製薬株式会社 | ピリドンカルボン酸誘導体の製造方法およびその中間体 |
| DE69936141T2 (de) * | 1998-06-30 | 2008-01-31 | Sloan-Kettering Institute For Cancer Research | Verwendung von dna-pk |
| US6670144B1 (en) | 1999-02-26 | 2003-12-30 | Cyclacel, Ltd. | Compositions and methods for monitoring the phosphorylation of natural binding partners |
| US6570002B1 (en) | 1999-02-26 | 2003-05-27 | The Johns Hopkins University | Inhibitor of programmed cell death |
| US7163801B2 (en) * | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
| US6479541B1 (en) * | 2000-03-30 | 2002-11-12 | Baxter International | Amiodarone-containing parenteral administration |
| EP1283903A1 (en) * | 2000-05-20 | 2003-02-19 | Cancer Research Technology Limited | Drug screening systems and assays |
| WO2002020500A2 (en) * | 2000-09-01 | 2002-03-14 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| WO2002028387A1 (en) * | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
| JP2004512381A (ja) | 2000-11-02 | 2004-04-22 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | Ｈｓｐ９０インヒビターの使用により細胞毒性剤の効力を増強させる方法 |
| WO2003089573A2 (en) * | 2002-04-05 | 2003-10-30 | Fishel Richard A | Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
| US8404681B2 (en) * | 2003-03-24 | 2013-03-26 | Luitpold Pharmaceuticals, Inc. | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors |
| ATE451924T1 (de) * | 2004-03-15 | 2010-01-15 | Sunesis Pharmaceuticals Inc | Sns-595 und anwendungsverfahren |
| US8580814B2 (en) | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| AU2006287149B2 (en) | 2005-09-02 | 2013-05-23 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| US8124773B2 (en) | 2006-06-12 | 2012-02-28 | Sunesis Pharmaceuticals, Inc. | 1,8-naphthyridine compounds for the treatment of cancer |
| WO2008016678A2 (en) | 2006-08-01 | 2008-02-07 | Sunesis Pharmaceuticals, Inc. | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| JP2009545601A (ja) | 2006-08-02 | 2009-12-24 | サネシス ファーマシューティカルズ， インコーポレイテッド | （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の組合せ使用 |
| US8518872B2 (en) | 2007-10-22 | 2013-08-27 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy |
| CA2708264C (en) | 2007-12-10 | 2018-07-03 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| EP2382214B1 (en) | 2008-12-31 | 2017-07-19 | Sunesis Pharmaceuticals, Inc. | Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| JP5936862B2 (ja) | 2009-02-27 | 2016-06-22 | サネシス ファーマシューティカルズ， インコーポレイテッド | Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法 |
| CN101631081B (zh) | 2009-08-12 | 2011-06-08 | 华为技术有限公司 | 一种多级交换网 |
| UA110465C2 (en) * | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
| TW201120037A (en) | 2009-10-26 | 2011-06-16 | Sunesis Pharmaceuticals Inc | Compounds and methods for treatment of cancer |
-
2005
- 2005-03-14 AT AT05732554T patent/ATE451924T1/de active
- 2005-03-14 PL PL10177951T patent/PL2295056T3/pl unknown
- 2005-03-14 AU AU2005222607A patent/AU2005222607B2/en not_active Ceased
- 2005-03-14 NZ NZ549557A patent/NZ549557A/en not_active IP Right Cessation
- 2005-03-14 DK DK05732554.0T patent/DK1729770T3/da active
- 2005-03-14 BR BRPI0508700-7A patent/BRPI0508700A/pt not_active IP Right Cessation
- 2005-03-14 CN CN201410477839.4A patent/CN104324029A/zh active Pending
- 2005-03-14 HU HUE10177951A patent/HUE027266T2/en unknown
- 2005-03-14 ES ES05731600T patent/ES2358267T3/es not_active Expired - Lifetime
- 2005-03-14 PL PL05731600T patent/PL1725233T3/pl unknown
- 2005-03-14 PL PL05732554T patent/PL1729770T3/pl unknown
- 2005-03-14 EP EP05731600A patent/EP1725233B1/en not_active Expired - Lifetime
- 2005-03-14 CA CA2559652A patent/CA2559652C/en not_active Expired - Fee Related
- 2005-03-14 CN CN200910221540A patent/CN101703508A/zh active Pending
- 2005-03-14 CN CN201210307785.8A patent/CN103251589B/zh not_active Expired - Fee Related
- 2005-03-14 DK DK05731600.2T patent/DK1725233T3/da active
- 2005-03-14 KR KR1020067021270A patent/KR101169825B1/ko not_active Expired - Fee Related
- 2005-03-14 JP JP2007503972A patent/JP5096913B2/ja not_active Expired - Fee Related
- 2005-03-14 MX MX2011011851A patent/MX349188B/es unknown
- 2005-03-14 EP EP10177951.0A patent/EP2295056B9/en not_active Expired - Lifetime
- 2005-03-14 EP EP15202939.3A patent/EP3053579A1/en not_active Withdrawn
- 2005-03-14 DE DE602005025738T patent/DE602005025738D1/de not_active Expired - Lifetime
- 2005-03-14 DE DE602005018333T patent/DE602005018333D1/de not_active Expired - Lifetime
- 2005-03-14 PT PT05731600T patent/PT1725233E/pt unknown
- 2005-03-14 CA CA2954578A patent/CA2954578A1/en not_active Abandoned
- 2005-03-14 AT AT05731600T patent/ATE493982T1/de active
- 2005-03-14 SI SI200531244T patent/SI1725233T1/sl unknown
- 2005-03-14 ES ES05732554T patent/ES2334802T3/es not_active Expired - Lifetime
- 2005-03-14 SI SI200530890T patent/SI1729770T1/sl unknown
- 2005-03-14 ZA ZA200607248A patent/ZA200607248B/xx unknown
- 2005-03-14 JP JP2007503987A patent/JP5317472B2/ja not_active Expired - Fee Related
- 2005-03-14 CN CN200580015456.4A patent/CN1997368B/zh not_active Expired - Fee Related
- 2005-03-14 EP EP05732554A patent/EP1729770B1/en not_active Expired - Lifetime
- 2005-03-14 CA CA2559650A patent/CA2559650C/en not_active Expired - Fee Related
- 2005-03-14 WO PCT/US2005/008346 patent/WO2005089757A1/en not_active Ceased
- 2005-03-14 DK DK10177951.0T patent/DK2295056T5/en active
- 2005-03-14 CN CN201210307920.9A patent/CN103083316B/zh not_active Expired - Fee Related
- 2005-03-14 PT PT05732554T patent/PT1729770E/pt unknown
- 2005-03-14 WO PCT/US2005/008036 patent/WO2005089756A1/en not_active Ceased
- 2005-03-14 ES ES10177951.0T patent/ES2566973T3/es not_active Expired - Lifetime
- 2005-03-14 AU AU2005222622A patent/AU2005222622B2/en not_active Ceased
- 2005-03-14 US US11/080,283 patent/US7989468B2/en not_active Expired - Fee Related
- 2005-03-14 MX MXPA06010382A patent/MXPA06010382A/es active IP Right Grant
- 2005-03-14 US US11/080,102 patent/US7968565B2/en not_active Expired - Fee Related
- 2005-04-14 NZ NZ588060A patent/NZ588060A/en not_active IP Right Cessation
- 2005-09-02 US US11/218,653 patent/US20060063795A1/en active Pending
- 2005-09-02 US US11/218,387 patent/US20060025437A1/en active Pending
-
2006
- 2006-06-29 US US11/478,765 patent/US7829577B2/en not_active Expired - Fee Related
- 2006-09-07 IL IL177946A patent/IL177946A/en not_active IP Right Cessation
- 2006-10-12 NO NO20064647A patent/NO338058B1/no not_active IP Right Cessation
-
2010
- 2010-01-21 CY CY20101100063T patent/CY1109741T1/el unknown
-
2011
- 2011-02-03 CY CY20111100114T patent/CY1111263T1/el unknown
- 2011-03-22 AU AU2011201277A patent/AU2011201277B2/en not_active Ceased
- 2011-04-27 US US13/095,111 patent/US20110263524A1/en not_active Abandoned
- 2011-06-13 US US13/159,258 patent/US8669270B2/en not_active Expired - Fee Related
- 2011-06-17 JP JP2011135675A patent/JP2011225590A/ja active Pending
-
2012
- 2012-02-23 JP JP2012036919A patent/JP2012140442A/ja active Pending
-
2013
- 2013-03-11 US US13/794,583 patent/US8822493B2/en not_active Expired - Fee Related
-
2014
- 2014-02-03 US US14/171,673 patent/US20140378505A1/en not_active Abandoned
- 2014-04-25 JP JP2014091125A patent/JP5856644B2/ja not_active Expired - Fee Related
- 2014-08-18 US US14/462,439 patent/US9980949B2/en not_active Expired - Fee Related
- 2014-09-05 JP JP2014180862A patent/JP6261477B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-17 NO NO20150466A patent/NO339613B1/no not_active IP Right Cessation
- 2015-07-14 JP JP2015140309A patent/JP6352863B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-14 US US14/996,025 patent/US9757363B2/en not_active Expired - Fee Related
- 2016-09-26 IL IL248049A patent/IL248049A0/en unknown
- 2016-11-24 NO NO20161867A patent/NO20161867A1/no not_active Application Discontinuation
- 2016-12-21 JP JP2016248041A patent/JP2017095471A/ja active Pending
-
2018
- 2018-03-05 JP JP2018038834A patent/JP2018119977A/ja active Pending
- 2018-04-27 US US15/965,741 patent/US20180316309A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014148535A5 (enExample) | ||
| JP2014040437A5 (enExample) | ||
| GEAP202014690A (en) | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| JP2016508134A5 (enExample) | ||
| WO2008016702A3 (en) | Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic | |
| MX395482B (es) | Compuestos antiproliferativos y metodos de uso de los mismos | |
| JP2016539157A5 (enExample) | ||
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| WO2016161342A3 (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| WO2013123215A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
| EA201890458A1 (ru) | Композиции с усилителями проницаемости для доставки лекарств | |
| GEP20186838B (en) | 5-phenoxy-3h-pyrimidin-4-one derivatives and their usage as hiv reverse transcriptase inhibitors | |
| WO2005105213A3 (en) | Indole and azaindole derivatives with antitumor action | |
| PH12012502447A1 (en) | Tetrahydrocarboline derivative | |
| GEP20207172B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| EP4356912A3 (en) | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | |
| JP2009539994A5 (enExample) | ||
| WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
| NZ594829A (en) | Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity | |
| TW201613594A (en) | Pharmaceutical composition containing diamino heteroring carboxamide derivatives | |
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| JP2011500805A5 (enExample) | ||
| MX2010004350A (es) | Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion. | |
| PH12018502735A1 (en) | Liver delivery-based antiviral precursor drug nucleoside cyclophosphate compound and use thereof | |
| MX2022001261A (es) | Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb. |